GSK’s investigational antisense oligonucleotide, bepirovirsen, met its primary efficacy endpoints in two pivotal Phase III trials enrolling over 1,200 chronic hepatitis B patients across North America, Europe and Asia-Pacific. In both studies, a statistically significant proportion of patients achieved sustained functional cure—defined as loss of hepatitis B surface antigen and undetectable viral DNA at Week 48—compared to placebo (40% vs. 5% in Study A; 38% vs. 6% in Study B; p<0.001 for both). Safety data showed no new signals, with the most common adverse events being mild injection site reactions (reported in 12% of participants) and transient liver enzyme elevations in 8%. These results support a rolling regulatory submission in major markets beginning later this quarter, positioning GSK to address an estimated global patient population of 250 million chronically infected individuals.

GSK has entered an anchor partnership with AI specialist Noetik, licensing its suite of foundation models to enhance target identification, lead optimization and translational biomarker discovery across GSK’s oncology pipeline. Under terms of the agreement, GSK gains access to Noetik’s pre-trained generative and predictive algorithms and will deploy them across four R&D centers in the U.S. and U.K., potentially reducing early research timelines by 30–40%. Financial details were not disclosed, but the deal includes milestone payments tied to model performance and co-development options for up to three novel therapeutic assets. GSK expects initial AI-driven candidate nominations by mid-2026, aiming to bolster its goal of filing five new oncology IND applications by 2028.